Ultra-low-dose quadruple combination blood pressure lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. by Chow, CK et al.
© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://
creativecommons.org/licenses/by-nc-nd/4.0/        
The definitive publisher version is available online at https://doi.org/10.1016/j.ahj.2020.09.017
Page 1 of 20 
 
Ultra-low-dose quadruple combination blood pressure lowering therapy in 1 
patients with hypertension: The QUARTET randomized controlled trial protocol 2 
 3 
Clara K. Chow, PhD 1,2  4 
Emily R. Atkins, PhD 1,2   5 
Laurent Billot, PhD 2 6 
John Chalmers, PhD 2 7 
Graham S. Hillis, PhD 3 8 
Peter Hay, MBBS4  9 
Bruce Neal, PhD 2 10 
Mark Nelson, PhD 5 11 
Anushka Patel, PhD 2 12 
Christopher M. Reid, PhD 6 13 
Markus Schlaich, PhD 7 14 
Tim Usherwood, PhD 1 15 
Ruth Webster, PhD 2,8  16 
Anthony Rodgers, PhD 1,2 17 
Affiliations: 1 The Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Australia 18 
2. The George Institute for Global Health, UNSW, Australia 19 
3. Department of Cardiology, Royal Perth Hospital and University of Western Australia, Australia 20 
4. Castle Hill Medical Centre, NSW, Australia 21 
5. Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia 22 
6. School of Public Health, Curtin University, Perth, Australia 23 
7. Dobney Hypertension Centre, School of Medicine, University of Western Australia and Royal Perth Hospital 24 
8. Centre for Health Economics Research and Evaluation, University of Technology Sydney, Australia 25 
Page 2 of 20 
 
Corresponding author:  26 
Prof. Clara K Chow 27 
Rm No 2041, Research & Education Network, Westmead Hospital | Westmead | NSW | 2145 28 




  33 
Page 3 of 20 
 
Abstract  34 
High blood pressure is the leading cause of preventable morbidity and mortality globally. Many patients remain on 35 
single-drug treatment with poor control although guidelines recognize that most require combination therapy for blood 36 
pressure control. Our hypothesis is that a single-pill combination of four blood pressure- lowering agents each at a 37 
quarter dose may provide a simple, safe and effective blood pressure lowering solution which may also improve long 38 
term-adherence. The QUARTET (Quadruple UltrA-low-dose tReaTment for hypErTension) double-blind, active 39 
controlled, randomized clinical trial will examine whether ultra-low-dose quadruple combination therapy is more 40 
effective than guideline recommended standard care, in lowering blood pressure. QUARTET will enroll 650 participants 41 
with high blood pressure, either on no treatment or on monotherapy. Participants will be randomized 1:1 and allocated 42 
to intervention therapy of a single pill (quadpill) containing irbesartan 37.5mg, amlodipine 1.25mg, indapamide 0.625mg 43 
and bisoprolol 2.5mg or to control therapy of a single identical appearing pill containing irbesartan 150mg. In both arms 44 
step up therapy of open-label amlodipine 5 mg will be provided if BP is > 140/90 at 6 weeks. The primary outcome is 45 
the difference between groups in the change from baseline in mean unattended automated office systolic blood 46 
pressure at 12 weeks follow-up. The primary outcome and some secondary outcomes will be assessed at 12 weeks, 47 
there is an optional 12 months extension phase to assess longer term efficacy and tolerability. Our secondary aims are 48 
to assess if this approach is safe, has fewer adverse effects and better tolerability compared to standard care control. 49 
QUARTET will therefore provide evidence for the effectiveness and safety of a new paradigm in the management of 50 
high blood pressure.  51 
 52 
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Strengths and limitations of this study 55 
Strengths 56 
 Large, multi-site randomized trial with up to 12 months follow-up 57 
 Double-blind design 58 
 Comparison with current guideline-based blood pressure management 59 
 Objective measurement of the primary outcome  60 
 Embedded economic and acceptability evaluations  61 
Limitations 62 
 Single country study. A sister trial, QUARTET USA, will provide further information on generalizability. 63 
 Trial not powered for cardiovascular events.  64 
  65 
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Abbreviations 66 
ABP/ABPM ambulatory blood pressure /monitoring 67 
ACE-I  angiotensin converting enzyme inhibitor 68 
ARB  angiotensin II receptor blocker  69 
BB  beta-blocker  70 
CCB  calcium channel blocker  71 
DALY  disability-adjusted life-year 72 
DBP  diastolic blood pressure 73 
DSMC  data safety and monitoring committee 74 
eGFR  estimated Glomerular Filtration Rate 75 
GP  general practitioner  76 
QUARTET Quadruple UltrA-low-dose tReatment for hypErTension 77 
SBP  systolic blood pressure 78 
SD  standard deviation 79 
TZ  thiazide or thiazide-like diuretic 80 
  81 
  82 
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Introduction  83 
Burden of high blood pressure and treatment gaps  84 
High blood pressure is the leading cause of preventable morbidity and mortality globally.1 The benefits of blood pressure 85 
lowering in reducing cardiovascular events are unequivocal2  and there is clear evidence of greater benefits for 86 
combination-based therapy compared to monotherapy.3 Furthermore, numerous studies have indicated the benefits of 87 
more rapid control of blood pressure, and have shown that this is more likely to occur with use of combination therapy.4 88 
Yet, control of high blood pressure is poor, with only 1 in 3 on treatment achieving blood pressure targets.5-8   89 
Previous guidelines typically recommended initiating monotherapy, up-titration of dose, switching drugs if not tolerated, 90 
and adding other agents if needed.7 This often takes multiple visits to achieve target blood pressure – and studies show 91 
that most individuals remain on monotherapy and with inadequate blood pressure control.5 The largest global survey 92 
of hypertension practice showed only 34% of those treated for high blood pressure were controlled (SBP<140 and 93 
DBP<90mmHg), and 31% of treated patients were receiving combination therapy.5 The 2017 May Measurement Month 94 
blood pressure screening campaign included a convenience sample of 1.2 million across 34 countries, and found 54% of 95 
those treated had adequate blood pressure control. A 2013 survey of 31 international hypertension guidelines showed 96 
that 27 (87%) now recommend use of combination for initial treatment, but typically only as an option for patients 97 
at >20/10mmHg from goal.9 As 50 to 75% of patients require combination treatment for blood pressure control, there 98 
has been increasing interest in the initial use of combination therapy.10 Most recently the ESC/ESH guidelines 99 
recommended initial combination therapy for most people, except those with low cardiovascular risk and 100 
SBP<150mmHg and frail older adults.11 101 
There are multiple barriers to blood pressure control that are patient, healthcare system and physician related. Patient 102 
adherence is a major factor and is worsened by increased number of medications, complexity of dosing regimens and 103 
medication side effects.12,13 ‘Therapeutic inertia’, the reluctance of physicians to treat mild hypertension and up-titrate 104 
medications, is also a barrier to blood pressure control. A large study conducted in Western Europe and the US of more 105 
than 20,000 people with hypertension found that blood pressure control rates ranged from 31 to 63%, and only 15 to 106 
38% of instances of elevated blood pressure had up-titration during the visit.14 There is a clear need for improved 107 
strategies that will: a) make the treatment of high blood pressure more effective and easier to implement for doctors 108 
and patients; b) quickly and safely bring blood pressure under control and; c) increase long term adherence with therapy. 109 
We hypothesize that a single-pill combination of four blood pressure lowering agents at quarter dose may achieve these 110 
goals. 111 
Rationale for very low-dose combination therapy 112 
Dose response data on blood pressure reduction 113 
Pharmacological dose response curves for blood pressure lowering drugs indicate that a quarter-dose has at least half 114 
the blood pressure-lowering effect of a standard dose (usual maintenance dose) but with much fewer side effects.3  115 
A systematic review of all randomized trials of quarter dose blood pressure lowering identified a total of 42 trials, 38 of 116 
single quarter-dose comparisons, seven of dual quarter-dose comparisons and two of a quadruple quarter-dose 117 
combination.15 Compared to placebo, single quarter dose therapy reduced blood pressure by 5/2 mmHg (p<0.0001) 118 
with no increase in adverse events. Dual quarter-dose therapy was similarly efficacious as standard-dose monotherapy. 119 
Two studies of quadruple quarter-dose therapy have been published. One unblinded pilot with four control groups of 120 
standard-dose monotherapies of the components showed a reduction of 13/8mmHg compared to the average 121 
reduction of all four controls after four weeks.16 The other, our pilot, a double-blinded placebo-controlled cross-over 122 
trial in people with newly diagnosed hypertension showed a reduction of 22/13mmHg after four weeks active treatment 123 
versus placebo.17   124 
There is strong evidence that the blood pressure lowering effects of different classes of drugs are independent and fully 125 
additive.15,18 The effects of adding a second blood pressure lowering agent are closely concordant with those predicted 126 
by independent effects, occur across all pairs of medication classes, and are about five times more effective than 127 
doubling the dose of the first agent.18 The additive effects across three classes of low-dose drugs were also 128 
demonstrated in a placebo-controlled, crossover trial of three half-dose blood pressure drugs in 86 participants aged 129 
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over 50 years without a history of cardiovascular disease.19 Overall a 17.4/9.4 mmHg blood pressure reduction was 130 
observed, compared to the anticipated 17.9/9.5 mmHg decline expected from the cumulative effects of the three 131 
separate agents. 132 
Dose response data on adverse effects 133 
Avoiding or minimising adverse effects is critical to long-term adherence for blood pressure lowering, given that high 134 
blood pressure is typically symptomless. Blood pressure lowering medications rarely cause adverse effects when used 135 
at low dose but each doubling in dose typically leads to a steep increase in adverse effect rates.20 This contrasts to the 136 
dose response for blood pressure reduction whereby significant effects are seen at quarter-dose, with only a moderate 137 
dose response thereafter. For thiazide or thiazide-like diuretics (TZs), beta-blockers (BBs) and calcium-channel blockers 138 
(CCBs) there is a relatively steep increase in adverse effects across all dose ranges.20 Angiotensin converting enzyme 139 
inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are usually well tolerated at low and standard doses but 140 
are associated with more adverse effects at higher doses, with the exception of ACE-I-cough which is not dose-141 
dependent.21 142 
Few direct data have been published on the adverse effects of ultra-low doses of anti-hypertensive medications. 143 
Bennett et al. reviewed 15 studies that had data on adverse effects.15 Comparisons with placebo showed no difference 144 
in total adverse events for single quarter-dose (14 trials, n=1838), dual quarter-dose (6 trials, n=312), and quadruple 145 
quarter-dose (1 trial, n=19) therapy. Comparisons with standard-dose monotherapy showed significantly fewer adverse 146 
events overall for single quarter-dose (15 trials, n=1978) and dual quarter-dose (2 trials, n=290) therapy. Biochemical 147 
changes appear minimal with quarter-dose therapy compared to standard-dose monotherapy.15 These data suggest 148 
that dose-dependent adverse effects will be minimal with this intervention, and idiosyncratic reactions are uncommon 149 
with these component medications.  150 
Objective  151 
The primary objective of the Quadruple UltrA-low-dose tReatment for hypErTension (QUARTET) trial is to examine 152 
whether ultra-low-dose quadruple combination therapy (quadpill) is more effective than guideline recommended 153 
therapy with an ARB plus a CCB if required in lowering blood pressure. Our secondary aim is to assess if this approach 154 
is safe and has fewer adverse effects compared to standard care. 155 
Methods 156 
Trial design  157 
This is a 12-week double blind randomized controlled trial of 650 patients with high blood pressure. Participants are 158 
randomized in a 1:1 allocation ratio using a central computer-based service, to initial therapy with quadpill or to a 159 
standard dose of an ARB, with a CCB added as required, as per current guideline recommendations (Figure 1). The 160 
primary outcome is reduction in mean office systolic blood pressure (SBP) measured using Omron HEM-907 at 12 weeks. 161 
Secondary outcomes include: the proportion of participants with controlled blood pressure (SBP<140mmHg and 162 
diastolic blood pressure [DBP] <90mmHg) at 6 weeks and 12 weeks, ambulatory blood pressure (ABP) measures at 12 163 
weeks, tolerability and the occurrence of adverse events. Learnings from the quadpill pilot informed the design and 164 
conduct of the present trial.17 165 
Extension study 166 
An extension study to 12 months follow-up involves two more visits, at 26 and 52 weeks after randomization to 167 
examine longer term efficacy and tolerability.  168 
Participants 169 
Eligibility criteria 170 
The study enrolled the first participant on 8th June 2017, and the last participants are expected to complete follow-up 171 
by 30th November 2020. Currently 575 (88%) participants have been randomized and 421 have agreed to continue in 172 
the extension study. At the time of submission COVID-19 has impacted study recruitment as health services have paused 173 
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non-essential activities (from mid-March 2020) to minimise infection risk. This may increase the likelihood of stopping 174 
the trial before the recruitment target is reached 175 
Inclusion criteria 176 
 Adults (≥18 years)  177 
 Previous documentation of hypertension or high blood pressure (SBP 140-179mmHg and/or DBP 90-109 mmHg) 178 
from general practitioner (GP), pharmacist or other health care professional 179 
 And either: 180 
o A measure of office SBP 140-179mmHg and/or DBP 90-109 mmHg documented by study staff in the 181 
last 12 weeks with a study automatic BP device or;  182 
o A recorded measure of daytime average SBP ≥ 135 mmHg and/or DBP ≥ 85 mmHg on a 24-hour 183 
ambulatory BP monitoring device in the last 12 weeks. 184 
 And one of the following: 185 
o Treatment naïve (i.e. never treated); 186 
o Currently not on treatment (not taken in last 4 weeks); 187 
o Currently taking one BP lowering drug (that is any of the following drug classes: ACE-I, ARB, CCB, BB, 188 
aldosterone antagonist, alpha-blocker) at any dose.  189 
 190 
Exclusion criteria 191 
 Contraindication to irbesartan, amlodipine, indapamide or bisoprolol 192 
 Evidence of secondary cause of hypertension;  193 
 Estimated Glomerular Filtration Rate [eGFR]<50 mL/min/1.73m2,  194 
 Raised serum potassium (above local laboratory normal limit) 195 
 Women who are pregnant, breast feeding and/ or of childbearing potential and not using medically acceptable 196 
form of contraception throughout the study  197 
 Concomitant illness, physical impairment or mental condition which in the opinion of the study team/ primary 198 
care physician could interfere with the conduct of the study including outcome assessments  199 
 Participation in a concurrent interventional medical investigation or clinical trial. Patients in observational, 200 
natural history and/or epidemiological studies not involving an intervention are eligible. 201 
 Participant’s primary care doctor or other responsible physician believes it is not appropriate for participant to 202 
switch current monotherapy or initiate study drug. 203 
 Inability or unwillingness to provide written informed consent 204 
 Unable to complete study procedures including 24-hour ABPM 205 
 Definite indication for one or more components of the quadpill 206 
We amended exclusion criteria in November 2017 to ensure participants in an influenza vaccination study were not 207 
precluded from participation in the trial.  208 
 Participation in a concurrent clinical trial of an investigational medical product. Patients in trials of approved 209 
medical products, or in observational, natural history and/or epidemiological studies not involving an 210 
intervention are eligible. 211 
Changes to inclusion and exclusion criteria to facilitate recruitment 212 
In June 2018 we further amended inclusion criteria to allow lower BP entry for those on monotherapy, as these 213 
participants are considered not-at-target within Australian guidelines.22 214 
 Adults (≥18 years)  215 
 Previous documentation of hypertension or high blood pressure (SBP 140-179mmHg and/or DBP 90-109 mmHg) 216 
from general practitioner (GP), pharmacist or other health care professional 217 
 And either meeting criterion A or B: 218 
o Criterion A: In treatment naïve (i.e. never treated) or in patients currently not on treatment (not taken 219 
in last 4 weeks) either: 220 
  A measure of Clinic SBP 140-179mmHg and/or DBP 90-109mmHg documented by study staff 221 
in the last 12 weeks with a study automatic BP device OR  222 
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  A recorded measure of daytime average SBP ≥135mmHg and/or DBP ≥85mmHg on a 24-223 
hour ambulatory blood pressure monitoring (ABPM) device in the last 12 weeks  224 
o Criterion B: In patients currently taking one BP lowering drug ‘monotherapy’ either: 225 
 A measure of Clinic SBP 130-179mmHg and/or DBP 85-109mmHg documented by study staff 226 
in the last 12 weeks with a study automatic BP device OR  227 
 A recorded measure of daytime average SBP ≥125mmHg and/or DBP ≥80mmHg on a 24-228 
hour ABPM device in the last 12 weeks. 229 
Setting, locations and recruitment 230 
Participants are recruited from community general practices and outpatient clinics. Current active sites are listed in 231 
the appendix. There is a total of 10 sites in 4 of the 8 states and territories of Australia (New South Wales, Victoria, 232 
Tasmania and Western Australia), with 3 of these based in primary care and the rest in hospital or university locations. 233 
We employ several methods to identify potentially eligible participants. This includes community advertising and 234 
awareness campaigns (using print and electronic media advertisements and radio), referral by clinicians aware of the 235 
study (advertising through clinical trial sites and communication media to health professionals) and screening of 236 
relevant patient lists by clinical investigators for potentially eligible patients. Participants are not paid for their 237 
participation. Participants may be reimbursed for travel. 238 
 239 
Study treatment  240 
Patients are randomized to a) an encapsulated single pill (quadpill) containing irbesartan 37.5mg, amlodipine 1.25mg, 241 
indapamide 0.625mg and bisoprolol 2.5mg; or to b) an identical capsule containing irbesartan 150mg.  At 6 weeks, if 242 
the blood pressure is greater than 140/90 mmHg in either arm open label amlodipine 5mg is added: this is provided as 243 
an additional pill.  244 
We selected quarter standard doses of irbesartan, amlodipine, indapamide, and bisoprolol. The first three were chosen 245 
as the most commonly prescribed ARB, CCB, and TZ in Australia (PBS Information Management Section Pharmaceutical 246 
Policy Branch, 2013).  Standard dose was determined following the method of Bennett et al.15 While hydrochlorothiazide 247 
is included in a number of fixed dose combinations, some recent guidelines23 and literature recommend indapamide or 248 
chlorthalidone, principally on the basis that some data suggest more cardiovascular event reduction with these 249 
agents,24,25 though a recent paper suggests no difference.26 The additional blood pressure reduction expected from 250 
including a quarter-dose of a different class of drug is about three times as great as would be achieved by doubling the 251 
dose of any other component.15 We chose the 4th agent to be a BB, due to its long duration of action, relatively minimal 252 
side effects at a quarter dose. The choice of a beta-blocker as a 4th agent of choice is also consistent with a number of 253 
international hypertension guidelines which specify Beta-blocker use after renin angiotensin system blockers, CCBs and 254 
thiazide type diuretics.22,27,28 We chose bisoprolol over atenolol due to its longer duration of action. The other major 255 
consideration was use of off-patent components to minimize costs. 256 
The control group follows the recommendations of the current Australian guidelines,22,29 i.e. initiating with an ACE-I or 257 
ARB, and if blood pressure is not controlled adding a CCB. This approach is also consistent with the 2011 NICE 258 
Hypertension Guidelines, and among the preferred treatment options in the 2013 JNC-8 Guidelines and the 2013 259 
ESC/ESH Guidelines, which were current at the inception of this study.23,30,31 We chose irbesartan as it is the most 260 
commonly prescribed ARB in Australia and amlodipine because it is the most commonly prescribed CCB.  261 
Patients who are on monotherapy at time of recruitment will be asked to stop their treatment while they are taking 262 
the study treatment. The drug is provided to both intervention and control arms at no cost to the participant. 263 
Medications are provided in quantities of 99 tablets at 3 monthly intervals. That is a medication kit is given to patients 264 
at baseline, week 12 and at 6 months and 9 months in participants participating in the extension study. Each kit 265 
consists of 3 bottles comprising 33 tablets in each bottle. Most sites provide in-person pick-up of medications, and in 266 
selected sites in New South Wales (Westmead Hospital, Royal North Shore Hospital) and Western Australia (Sir 267 
Charles Gardiner Hospital, Royal Perth Hospital) medication is mailed to participants.  268 
  269 
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Preparation of study treatment  270 
The study drug has been made up by PCI Clinical Services (formerly Pharmaceutical Packaging Professionals), a 271 
Therapeutic Goods Administration Code of Good Manufacturing Practice audited facility approved for all stages of 272 
finished product manufacture for clinical trials. This company encapsulated the drugs listed for intervention and control 273 
arms into a single capsule, with additional placebos in the control capsule. Thus, both the intervention and control 274 
participants receive a single capsule that appears identical, inside and out, to all participants, their health care providers 275 
and trial personnel.  276 
Study procedures 277 
Patients are assessed for eligibility and randomized if criteria are met. Follow-up clinical assessments are conducted at 278 
6 and 12 weeks. The 6-week visit includes a clinic blood pressure measurement (3 unattended automated office 279 
measures) and recording of any changes in concomitant medications, adverse events, and health service use. At 6 weeks 280 
if clinic blood pressure is >140/90mmHg the researcher will alert the study doctor who will assess participant (BP and 281 
symptoms) and consider adding open-label amlodipine 5mg (consistent with current guidelines). The week 12 visit 282 
includes the above plus 24-hour ABPM, quality of life, and additional laboratory assessments sodium, potassium, 283 
chloride, bicarbonate, serum creatinine, eGFR (CKD-EPI formula), uric acid, liver function tests, and urine 284 
albumin/creatinine ratio. No central lab is used. Participants have an option to extend their involvement in the study to 285 
12 months after randomization, involving extra visits at weeks 26 and 52 (with comparable follow-up procedures to 286 
weeks 6 and week 12 visits, respectively). Extension involves continuing to receive the randomly allocated treatment, 287 
but with management through their general practitioner or site doctor. They may add additional drugs if clinically 288 
necessary with open label treatment added without the need to unblind randomized therapy. Adherence to medications 289 
is assessed by self-report and a pill count of returned study medications at end of study time points, that is week 12 290 
final visit and at 12 months the final visit of the extension study. Participants are asked how many days in the last 30 291 
days they have missed taking any of their regular medications, and similarly about missed medications in the last 7 days.  292 
During the study we will obtain information on self-reported health service utilization, and specifically ask if patients 293 
have seen and how frequently they have seen the following health providers – Practice nurse, General Practitioner, 294 
Doctor in public hospital emergency department (not admitted), Doctor in public outpatients clinic for any reason and 295 
Doctor in private specialist clinic for any reason. We also request consent to link data to MBS (Medical Benefits Schedule 296 
– listing of Medicare services subsidized by the Australian Government) and PBS (Pharmaceutical Benefits Scheme – 297 
listing of medicines subsidised by the Australian Government).  298 
Information is collected on serious adverse events and adverse events of special interest (see list in appendix). We 299 
specifically query participants about adverse events of special interest at each visit (6 week, 12 weeks and additional 300 
visits for extension participants 6 months and 12 months). Adverse events of special interest include: dizziness, 301 
hypotension, pedal oedema, muscle cramps, bradycardia, heart failure, hypersensitivity reactions (skin rashes, itching), 302 
gastrointestinal complaints (nausea, vomiting, diarrhea), musculoskeletal complaints, headaches.  Adverse events are 303 
not adjudicated. The EuroQol Group (EQ-5D-3L) Quality of Life questionnaire is completed by participants at their 304 
baseline, 12 week and final visits.  305 
 306 
Outcome measures and outcome assessment 307 
The primary and secondary outcomes are listed in Table 1.  308 
The blood pressure measurements are recorded using an Omron HEM907. An appropriate cuff size is selected for all BP 309 
measurements. First a measure of clinic blood pressure is observed and recorded by research staff. Then, automated 310 
office blood pressure is measured following the recommendations of the European Society of Hypertension/European 311 
Society of Cardiology and Australian National Heart Foundation.22,30 This requires the research staff to set the 312 
automated device to take three separate BP measurements while the researcher steps out of the room (unattended BP 313 
measurement). The Omron HEM907 is programmed to start the first measurement after five minutes of rest, then at 314 
one-minute intervals. The primary outcome “mean SBP” will be calculated using the average of these three unattended 315 
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measures. In addition, 24-hour ABPM is conducted at baseline, 12 and 52 week follow-up visits using a Suntech Oscar-316 
2 programmed to measure every 30 minutes while participant is awake, and hourly during sleep.32,33 317 
Sample size 318 
A sample size of 650 patients provides 90% power at p=0.05 to detect a difference between randomized groups of 4 319 
mmHg in the primary outcome, assuming a standard deviation (SD) of 15mmHg.34 A sample of 650 also has 85% power 320 
to detect a 3mmHg difference in average 24hr SBP (SD 12 mmHg)34 and 85% power to detect a 25% increase in the 321 
proportion with controlled blood pressure assuming 50% are controlled in the comparator group. All calculations allow 322 
for a 10% dropout or data loss rate.  It is assumed that irbesartan 150 mg and up-titration with the addition of amlodipine 323 
in 75% of participants in the control group will give an average reduction of 12mmHg from an average baseline SBP of 324 
150mmHg.35 Based on the information presented in the background, quadruple combination therapy will reduce SBP 325 
by at least 16mmHg.16,20  326 
The rate of all adverse events is predicted to be around 15% in the control group,35 and this study will have 90% power 327 
to rule out an increase of 5 percentage points (i.e. a non-inferiority margin of 20%) assuming the true incidence of 328 
adverse events in the quadpill group is 10% and a one-sided test with alpha=2.5%. The 10% incidence of adverse events 329 
is a conservative estimate from adding up the incidence of side effects from each treatment class at ½ standard dose 330 
described in a previous systematic review: BB 5.5%, TZ 2.0%, CCB 1.6% and ARB 0%.3  331 
Interim analyses, monitoring, and stopping guidelines 332 
The trial data safety and monitoring committee (DSMC) monitors safety data on an ongoing basis, with the analyses 333 
performed by an independent statistician from the George Institute for Global Health. The DSMC can recommend the 334 
Steering Committee of the QUARTET Study should continue the study unchanged, adjust the duration of follow-up, or 335 
terminate the study early if there is clear and substantial evidence of benefit, if the data suggests the risk of adverse 336 
events substantially outweighs the potential benefits, or for futility. The first DSMC meeting was held after 25% of 337 
participants completed 12 weeks follow up and recommended continuation of the study without modification.  338 
Randomization 339 
The unblinded statistician prepared a computer-generated randomization schedule stratified by site and using 340 
permuted blocks of variable size. This was loaded into the web-based data management system (IBM Clinical 341 
Development, Morrisville USA). Allocation concealment is maintained as only the unblinded statistician and unblinded 342 
data manager have access to the randomization list and allocation within the database.  343 
Participants are enrolled at sites by blinded staff, with participant randomization and study drug allocation conducted 344 
through the database with blinding maintained. The study drug kit numbering is separate to the randomization 345 
sequence to prevent the kit allocation potentially unblinding site staff. The investigators, project management, site staff, 346 
and participants are blinded to the randomization sequence and treatment allocation.  347 
Statistical methods 348 
The main analyses of study outcomes will be conducted according to the principle of intention-to-treat.  The primary 349 
analysis of change in SBP at 12 weeks will be performed using an analysis of covariance including the treatment arm 350 
and baseline SBP as a covariate. Continuous secondary outcomes will be analyzed similarly. Additional analyses will 351 
include all follow-up measurements in a longitudinal model including treatment arm, visit, and a treatment by visit 352 
interaction term as well as the baseline measurement. Within-patient correlations will be modelled using generalized 353 
estimating equations or random effects.  A similar approach will be applied to binary endpoints (e.g. blood pressure 354 
control) with log-binomial regression used in place of linear regression. A per-protocol analysis will be performed to 355 
provide information on the difference in efficacy between the two study treatments. There will also be pre-defined 356 
subgroup analyses, including by baseline blood pressure, gender, age, diabetes, education and by BP lowering treatment 357 
at baseline (no treatment versus monotherapy). A detailed analysis plan will be finalized prior to unblinding. 358 
 359 
Page 11 of 20 
 
Economic evaluation 360 
Cost-effectiveness and cost-utility analysis 361 
An incremental cost-effectiveness analysis will be used to compare the costs and outcomes of the treatment arms from 362 
a health system perspective. This will consider the cost per mmHg reduction in systolic blood pressure and the cost per 363 
quality adjusted life-year gained for quadpill versus monotherapy to facilitate comparison with other interventions. 364 
Costs will be determined through the collection of resource use during the study period and estimates of commercial 365 
costs for the quadpill. Information on hospital admissions, doctors’ visits and medications is collected at follow-up visits.  366 
Acceptability evaluation 367 
A semi-quantitative survey and in-depth interviews will be conducted to assess the acceptability of quadpill, and to 368 
identify which factors are important to participants and health providers in blood pressure reduction. Patient 369 
acceptability is a critical component of healthcare innovation. Patients and health providers in the study will be invited 370 
to answer questions assessing their perceptions, experience and the degree of engagement with the intervention at the 371 
completion of the trial. Patients and health providers will be invited to participate in semi-structured interviews on 372 
perceptions of the utility and acceptability of the intervention program. Examples of questions are included in the 373 
appendix. Interviews will be recorded and transcribed, then coded using NVivo. From the coded data key themes will 374 
be identified. 375 
Trial management, funding, and sponsorship 376 
The trial conduct is overseen by a steering committee (list in Appendix). The central coordinating center ensures 377 
implementation of the study according to the protocol, timelines and recruitment targets. We use an electronic data 378 
management system incorporating study checks and omissions. An independent data and safety monitoring committee 379 
meets regularly to assess emerging evidence on safety and efficacy. The QUARTET trial received primary funding from 380 
the National Health and Medical Research Council Australia (APP1100377). Investigators also received support from 381 
NHMRC program and investigator fellowships to enable the study (see Funding statement). The University of Sydney is 382 
the current study sponsor. 383 
Trial registration, human research ethics, and dissemination plan 384 
The QUARTET trial is registered on the Australian New Zealand Clinical Trial Registry (ACTRN12616001144404). The 385 
Western Sydney Local Health District Human Research Ethics Committee provides lead ethics approval 386 
(HREC/15/WMEAD/422).   387 
The main trial results will be published in the name of the QUARTET Investigators with credit assigned to the 388 
collaborating investigators and other research staff. Publication authors must meet the International Committee of 389 
Medical Journal Editors guidelines for authorship. Presentations of the study findings will be made at national and 390 
international meetings concerned with the management of cardiovascular disease, and high blood pressure. Trial data 391 
will be made available through data access agreements established following approval through the Quartet Steering 392 
Committee. Trial data will not be publicly released or placed into an open-access repository. Trial data will be held by 393 
the University of Sydney for a minimum period of 15 years (or longer if required by applicable regulatory authorities).  394 
Discussion 395 
High blood pressure is the leading risk factor for lost healthy life years globally.1 For women it is the leading risk factor, 396 
with 90 million disability-adjusted life-years (DALYs), and the second leading risk factor in men with 124 million DALYs.36 397 
Although the global age-standardized death rate attributable to high SBP declined by 1.35% over the last 30 years, the 398 
number of deaths attributable to high SBP has increased globally over this time, with 10.4 million deaths in 2016.37 399 
Achieving sustainable and affordable reductions in SBP is key to addressing this leading risk factor for lost healthy life. 400 
The QUARTET trial is the first large-scale trial to examine a quadruple, quarter-dose regimen. This approach has many 401 
theoretical benefits, including greater efficacy and fewer side effects as well as pragmatic benefits that should improve 402 
adherence and decrease costs. If this new intervention achieves its conservative additional 4mmHg of blood pressure 403 
reduction compared to that conferred by optimal guideline-recommended care, such a difference could translate into 404 
an additional 15 to 20% reduction in cardiovascular events.3  405 
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There has been increasing acceptance of the role of dual anti-hypertensive combinations in blood pressure management 406 
both due to the observation that most patients require more than one agent to achieve BP control, and by trials showing 407 
early use of combination is beneficial.38   408 
Benefits of combination therapy 409 
It is apparent that people respond differently to different blood pressure classes,23,39 however it is difficult to determine 410 
which drug is most effective for each individual.40 A trial and error approach to finding an effective monotherapy 411 
regimen may contribute to low adherence. Combination therapy is more likely to provide a genuine good response 412 
more quickly and with less variability.  413 
Fewer medications, and single-pill combination therapy improve adherence. A recent meta-analysis of trials comparing 414 
combination pills containing two antihypertensive agents to separate pills demonstrated a significant improvement in 415 
adherence with combination therapy.41 Triple combinations are commercially available,42,43 however they have not 416 
included an entirely low-dose option. These products are targeted to the relatively small subpopulation of patients with 417 
severe or resistant hypertension not controlled on full doses of dual combination therapy, or those already on the three 418 
medications.43 419 
Some recent trials of low-dose combination therapy have demonstrated the potential of this strategy in other settings. 420 
The TRIUMPH trial evaluated a half-strength triple pill, but with several points of difference, most importantly the 421 
comparison against a variety of usual care options in Sri Lankan outpatient hospital care, with a focus on improving the 422 
access and affordability of blood pressure lowering medications in this setting.44 This study found 70% of participants in 423 
the triple pill group achieved their target blood pressure versus 55% in the usual care group,44 and the triple pill was 424 
cost-effective compared to usual care.45 The Quadpill Pilot trial was a placebo-controlled pilot study was conducted in 425 
treatment-naïve people with newly diagnosed high blood pressure in primary care.17 The ultra-low dose quadruple 426 
combination was very effective at lowering blood pressure in the short-term single center pilot study, hence the current 427 
study is needed. A sister trial, QUARTET USA (Clinicaltrials.gov NCT03640312), is currently underway in Chicago USA and 428 
an individual patient data meta-analysis is planned once both trials are completed.  429 
Conclusion 430 
If the intervention tested here is proven to be safe and effective, the trial results could be rapidly implemented, with 431 
immediate benefits in routine clinical practice. Similar therapy could be provided to patients using available medications, 432 
including existing dual combinations and the use of dose administration aids. Ultimately, most advantage will be gained 433 
from single pill formulations. The results of the current trial would stimulate the development of such products if the 434 
results were favorable.  435 
In summary, ultra-low-dose combination therapy has the potential to have a major impact on current poor rates of 436 
blood pressure control globally. The critical next step is direct evidence on effectiveness and safety in a large-scale 437 
randomized controlled trial, which the QUARTET trial aims to provide.  438 
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Table 
TABLE 1 PRIMARY AND SECONDARY OUTCOMES FOR THE QUARTET TRIAL 
Primary outcome 
Difference between groups in change in mean office systolic blood pressure from baseline to 12 weeks 
Secondary outcomes 
24-hour ambulatory blood pressure  a) Difference between groups in mean 24-hour SBP and DBP at 12 and 
52 weeks 
b) Difference between groups in mean change in 24-hour SBP and DBP 
from 0 to 12 weeks, 0 to 52 weeks and 12 to 52 weeks 
c) Difference between groups in mean daytime SBP and DBP at 12 and 
52 weeks  
d) Difference between groups in mean night-time SBP and DBP at 12 
and 52 weeks 
e) Difference between groups in daytime, night-time, and 24-hour BP 
load (percentage area under the blood pressure curve above normal 
day, night, and 24-hour values as per National Heart Foundation 
guidelines 
f) Difference between groups in  the proportion of non-dippers (night-
time BP is not more than 10% lower than average daytime BP as per 
National Heart Foundation guidelines) and coefficient of variability 
of BP 33  
Other blood pressure measures a) Difference between groups in mean automated office systolic (52 
weeks) and diastolic blood pressure (12 and 52 weeks).  
b) Difference between groups in standard clinic SBP/ DBP at 12 and 
52 weeks 
c) Hypertension control (% with SBP <140 mmHg and DBP <90 mmHg) 
at 6, 12, 26 and 52 weeks,  
d) Percentage requiring step-up treatment at 6 weeks 
e) Percentage requiring step-up blood pressure lowering treatment 
over 52 weeks 
f) Percentage with both BP control (as defined above) and no adverse 
events.  
g) Difference between groups in SBP and DBP variability 
Tolerability a) Difference between groups in potentially related side-effects 
(dizziness, blurred vision, syncope/ collapse/ fall, chest pain/ 
angina, shortness of breath, cough, wheeze, ankle edema, skin rash, 
itching, gout, hyperkalemia, hypokalemia, hyponatremia, other) 
b) Difference between groups in mean potassium, uric acid, blood 
glucose, cholesterol and fractions, ALT, AST, UACR (Urine albumin-
to-creatinine ratio) and creatinine levels. 
c) Difference between groups in participant withdrawals from 
treatment  
Safety Percentage with any severe adverse event 
Medication adherence Self-reported measures and pill counts 
Cost-effectiveness The ratio of the difference in costs and outcomes between treatment 
arms 
Patient and prescriber acceptability End of study feedback questionnaires 
Note: Key secondary outcomes have been put in bold  




Figure 1 Trial Schema 
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 Prof Clara Chow (Chair) 
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Tasmania 
 University of Tasmania, Hobart 
Victoria 
 Monash University, Caulfield 
Western Australia 
 Curtin University, Bentley 
 Royal Perth Hospital, Perth 
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Harms  
All serious adverse events (SAEs) and adverse events of special interest (AESI) experienced by a participant after the 
informed consent document is signed and until the end of the study at week 12 or 52 will be collected and reported to 
the CCC as per applicable ICH GCP and applicable regulatory guidelines. If an SAE is unresolved at the conclusion of the 
study, a clinical assessment will be made by the medical monitor as to whether continued follow up of the SAE is 
warranted. SAE criteria, definitions and guidance for reporting are outlined in section 1 to 4  
 
1. Adverse event (AE)  
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with 
this treatment. Therefore, an AE can be any unfavourable and unintended sign (including an abnormal laboratory 
finding, for example), symptom, or disease temporally associated with the use of an investigational product, whether 
or not considered related to the investigational product. This definition includes intercurrent illnesses or injuries and 
exacerbation of pre-existing conditions.  
 
2 Adverse Events of Special Interest (AESI)  
The expected adverse reactions to the BP lowering medications that will be used in QUARTET are well known 
(Appendix 2). To better assess participants’ tolerability to the study medications the following AESI’s and whether they 
are new or ongoing from baseline will be reported to the CCC regardless of severity and seriousness:  
 Dizziness  
 Hypotension  
 Pedal Oedema  
 Headache  
 Muscle cramps  
 Bradycardia  
 Worsening of heart failure  
 Hypersensitivity reactions (skin rashes, itching)  
 Gastrointestinal complaints  
 Musculoskeletal trauma  
 
3 Serious Adverse Event (SAE)  
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose:  
 results in death  
 is life threatening in the opinion of the attending clinician (i.e. the patient was at risk of death at the time of the 
event; it does not refer to an event that might hypothetically have caused death had it been more severe)  
 requires inpatient hospitalisation or prolongation of existing hospitalisation (Any hospitalisation that was planned 
prior to randomisation will not meet SAE criteria. Any hospitalisation that is planned post randomisation will meet 
the SAE criteria)  
 results in persistent or significant disability or incapacity  
 results in congenital anomaly or birth defect (Note that the females in the study population are likely to be post-
menopausal)  
 is an important medical event in the opinion of the attending clinician that is not immediately life-threatening and 
does not result in death or hospitalisation but which may jeopardise the patient or may require intervention to 
prevent one of the other outcomes listed above  
 
An adverse event that meets the above categories between when the informed consent form is signed, the end of 
study visit at week 12 or at 26 and 52 weeks if patient is participating in the study extension and until the 28 days after 
the study drug discontinued will be reported as an SAE. All SAEs are required to be reported to the sponsor team 
within 24 hours of the study team first becoming aware of the event. The SAE will also be required to be reported to 
the relevant HREC/ IRBs within the timeframe specified in the relevant committee guidelines. If irbesartan or the LDQT 
is discontinued as a result of an AE, the study team will document all events leading to the discontinuation of 
treatment. Adverse events which do not fall into these categories are defined as non-serious.  
 
4 Suspected Unexpected Serious Adverse Reaction (SUSAR)  
An unexpected adverse reaction (UAR) is an adverse reaction, the nature or severity of which is not consistent with the 
applicable product information. Refer to (Quartet protocol, Appendix 2) for a list of expected adverse reactions for the 
interventions used in this protocol.  
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A Suspected Unexpected Serious Adverse Reaction is any UAR that at any dose meets the definition of an SAE (refer to 
section 3). Any event that meets the definition of a SUSAR between when the informed consent form is signed and the 
end of study visit at week 12 or week 52 will be reported to the local HREC/ IRB and the relevant regulatory authorities 
as per local requirements and ICH Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.  
 
 
Examples of questions asked of providers and participants to assess acceptability of the quadpill intervention 
Examples of questions asked of participants include: 
- During the trial, how easy did the participant find it to take the trial medications? 
- If the LDQT is available to be prescribed by participant’s usual doctor, how likely would the participant be to 
request it?  
- Are there any other comments the participant had about the LDQT? 
Examples of questions addressed to healthcare providers about the quad pill include: 
- What do you think are the potential benefits of LDQT or your concerns about LDQT? 
- If LDQT was available, in what circumstances would you prescribe it or what evidence would you require to 
start prescribing LDQT? 
- What do you consider to be important factors in patients’ decisions to take blood-pressure lowering 
medications? 
